Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
RegulatoryapprovedIBTROZIPositive
AI Analysis
Summary
Nuvation Bio announced FDA approval of a supplemental new drug application for IBTROZI (taletrectinib) with updated duration of response data in TKI-naïve advanced ROS1-positive non-small cell lung cancer.
Outcome Details
FDA Approval of Supplemental New Drug Application with updated duration of response data
Importance:8/10
Sentiment:
0.90
FDA approvalsNDAIBTROZIROS1-positive NSCLCregulatory
Related Companies
Read the original article
Published by yahoo_finance on September 17, 2026 11:30 AM